<i>In vivo</i> selection of anti-glioblastoma DNA aptamers in an orthotopic patient-derived xenograft model.

ABSTRACT: Glioblastoma (GBM) is the most common and aggressive primary malignant brain tumor of adults. Current therapeutic options yield dismal prognoses that have remained essentially unchanged over nearly two decades. Diffuse growth patterns, high intratumoral heterogeneity, and variable blood-brain barrier integrity limit treatment efficacy, creating challenges that rational small molecule design has not overcome. Antibody-drug conjugates have shown some promise, leading us to hypothesize that smaller folded DNA aptamers, developed in vivo via principles of natural selection, might eventually have advantages for drug delivery. Here, we document the first in vivo DNA aptamer selection involving an orthotopic patient-derived xenograft GBM mouse model to identify tumor-homing DNA apta

SUBMITTER: Doherty CD 

PROVIDER: S-EPMC11833697 | biostudies-literature | 2025 Mar

REPOSITORIES: biostudies-literature